GDC-0712

GDC-0712 is a potent and selective small molecule inhibitor of the MET receptor tyrosine kinase (also known as hepatocyte growth factor receptor, HGFR). Developed by Genentech, it was primarily investigated in preclinical models for its ability to block MET phosphorylation and downstream oncogenic signaling pathways, including MAPK and PI3K. Research has demonstrated that GDC-0712 can suppress tumor growth in pancreatic cancer xenograft models, particularly when used in combination with other targeted agents such as MEK inhibitors (e.g., cobimetinib/GDC-0973) or EGFR inhibitors (e.g., erlotinib). By inhibiting MET, GDC-0712 disrupts the HGF-mediated signaling that drives tumor cell proliferation, survival, and invasive growth.